The official FDA label for Rhofade is the source of the day-29 response rates, the year-long safety figures, and the warnings about use in people with heart or circulation problems. Unlike the Mirvaso label, it does not carry a warning about redness returning worse than before treatment.
Prescribing information: RHOFADE (oxymetazoline hydrochloride) cream, 1%. EPI Health. DailyMed, U.S. National Library of Medicine.